BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 30152676)

  • 1. Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy.
    Phan M; Watson MF; Alain T; Diallo JS
    ACS Infect Dis; 2018 Oct; 4(10):1448-1467. PubMed ID: 30152676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
    Feola S; Russo S; Ylösmäki E; Cerullo V
    Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The two-faces of NK cells in oncolytic virotherapy.
    Marotel M; Hasim MS; Hagerman A; Ardolino M
    Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and application of oncolytic viruses for cancer immunotherapy.
    Ylösmäki E; Cerullo V
    Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
    Selman M; Rousso C; Bergeron A; Son HH; Krishnan R; El-Sayes NA; Varette O; Chen A; Le Boeuf F; Tzelepis F; Bell JC; Crans DC; Diallo JS
    Mol Ther; 2018 Jan; 26(1):56-69. PubMed ID: 29175158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates to the antitumor mechanism of oncolytic virus.
    Bai Y; Hui P; Du X; Su X
    Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virotherapy: From single agents to combinatorial treatments.
    Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
    Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of the efficacy of viro-immunotherapy: A review.
    de Graaf JF; Huberts M; Fouchier RAM; van den Hoogen BG
    Cytokine Growth Factor Rev; 2020 Dec; 56():124-132. PubMed ID: 32919831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Viruses and Cancer Immunotherapy.
    Malhotra J; Kim ES
    Curr Oncol Rep; 2023 Jan; 25(1):19-28. PubMed ID: 36441447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
    Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
    Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
    Oh CM; Chon HJ; Kim C
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.